NEW YORK (GenomeWeb News) – Proteome Systems’ shareholders have agreed to change the name of the company to Tyrian Diagnostics in order to reflect its shift toward a biomarker-based diagnostics business, the company said today.
Tyrian Diagnostics said the renaming completes the moves the company has been making to focus on biomarkers.
“The divestiture of the technology platform and an exit from the therapeutic business enabled the allocation of the appropriate resources to achieve corporate growth,” company CEO Jenny Harry said in a statement.
The Sydney, Australia-based company said in August it would shut down its drug development business and would close its office in Boston.
The company said at the time that it would retain the rights to a portfolio of assets covering compounds for dermatological and neurological indications, and that it would consider out-licensing opportunities.
The company’s ticker symbol on the Australian exchange will change from ASX-PXL to TDX on Nov. 19.